Better Adherence to Combination Therapy for Hypertension
Author Information
Author(s): Bimal V Patel, Rosemay A Remigio-Baker, Patrick Thiebaud, Ronald Preblick, Craig Plauschinat
Primary Institution: MedImpact Healthcare Systems, Inc.
Hypothesis
Does fixed-dose combination therapy improve patient persistence and adherence compared to diuretic monotherapy?
Conclusion
Patients starting on fixed-dose combination therapy with HCTZ showed better persistence and adherence than those on HCTZ alone.
Supporting Evidence
- HCTZ patients had the lowest persistence at 29.9% compared to 52.6% for ARB/HCTZ.
- Adherence was lowest for HCTZ patients at 24.2% compared to 43.9% for BB/HCTZ.
- Patients on fixed-dose combinations stayed on therapy an average of 2.5 months longer than those on HCTZ alone.
Takeaway
If you take two medicines together for high blood pressure instead of just one, you're more likely to keep taking them and feel better.
Methodology
This was a retrospective, population-based study using pharmacy claims data to compare adherence and persistence between HCTZ monotherapy and fixed-dose combinations.
Potential Biases
Potential selection bias due to unmeasured factors influencing treatment choice.
Limitations
The study relied on pharmacy claims data, which may not accurately reflect actual medication intake, and lacked patient blood pressure data.
Participant Demographics
Mean age was 53.7 years; 66.5% were female.
Statistical Information
P-Value
p<0.01
Confidence Interval
0.36, 0.38
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website